Industry Bulletin
|
Beckley Psytech Limited, which uses psychedelic medicines to treat neurological and psychiatric disorders, partnered with Empatica, Inc., which provides a remote monitoring wearable device for people with neurological conditions. The partnership is intended to collect and analyze behavioral and physiological data in Beckley Psytech’s future clinical trials. This partnership will utilize Empatica’s medical-grade EmbracePlus wearable and software, to identify and measure passive behavioral and physiological signals among people participating in a Phase 2 clinical trial. Beckley Psytech is evaluating the use of 5-MeO-DMT in combination with psychotherapy in the treatment of treatment resistant depression (TRD). The strategic partnership with Empatica is… Beckley Psytech Partners With Empatica To Deliver Personalized Consumer Monitoring For Clinical Trial Of Psychedelic For Treatment Resistant Depression
Content Restricted
You must be a Free or Elite member to view this resource.
Log In | Sign up or learn more about membership options.
